More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?
ABSTRACTHaploidentical hematopoietic can be conducted on an outpatient basis but the two main reasons to accept into the hospital a patient in this setting are complications of the hematological toxicity and/or the cytokine-release syndrome. With the aim of reducing the post-transplant cyclophospham...
Main Authors: | Moisés Manuel Gallardo-Pérez, César Homero Gutiérrez-Aguirre, Juan Carlos Olivares-Gazca, Guillermo José Ruiz-Argüelles |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2313357 |
Similar Items
-
Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?
by: Juan Carlos Olivares-Gazca, et al.
Published: (2023-12-01) -
Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease
by: Kristy E. Gilman, et al.
Published: (2023-01-01) -
Comparison of Post-transplant Cyclophosphamide Containing Immunosuppressive Regimen with Standard Immunosuppressive Regimen in Allogeneic Stem Cell Transplantation from Matched Sibling Donor
by: Osman KARA, et al.
Published: (2021-12-01) -
Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease
by: Yijun Cai, et al.
Published: (2024-02-01) -
Current status of conditioning regimens in haploidentical hematopoietic cell transplantation
by: Junichi Sugita, et al.
Published: (2024-12-01)